Description
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
This trial is available at multiple Sutter Locations. Please contact one of the following about Study NRG GY018
San Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org
PAMF/Fremont: Tanya Pozniansky pozniat@sutterhealth.org
East Bay: Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: Kirsten Babski babskik@sutterhealth.org
Modesto: Adrienne Palos PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals1@sutterhealth.org
San Mateo: StephanieCasal CasalSL@sutterhealth.org and Bonnie Chan ChanBW@sutterhealth.org
Santa Rosa: Patricia Grinnell GrinneP@sutterhealth.org
View study details on ClinicalTrials.gov
Principal Investigator
Recruitment Status
Active, Recruiting
Start Date
February 03, 2020